Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.55 |
| ▸ | RAB9A | P51151 | 10/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5834702 | 0.90 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2PKMNPSR1 | |
| SCHEMBL1990188 | 0.83 | KDM4E (0.53) | NPC1RAB9ASMN1; SMN2PKMNPSR1 | |
| SCHEMBL18013087 | 0.83 | ELANE (0.63) | NPC1RAB9ASMN1; SMN2PKMNPSR1 | |
| SCHEMBL5021495 | 0.80 | ELANE (0.67) | NPC1RAB9ASMN1; SMN2PKMNPSR1 | |
| SCHEMBL30583378 | 0.80 | ELANE (0.67) | NPC1RAB9ASMN1; SMN2PKMNPSR1 | |
| SCHEMBL30583373 | 0.80 | POLB (0.51) | NPC1RAB9ASMN1; SMN2PKMNPSR1 | |
| SCHEMBL18013093 | 0.80 | ELANE (0.65) | NPC1RAB9ASMN1; SMN2PKMNPSR1 | |
| SCHEMBL25056911 | 0.79 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2PKMNPSR1 | |
| SCHEMBL5139452 | 0.79 | ELANE (0.64) | NPC1RAB9ASMN1; SMN2PKMNPSR1 | |
| SCHEMBL24590190 | 0.79 | PCSK9 (0.50) | NPC1RAB9ASMN1; SMN2PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468367-B2 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-12-23 | — | — | US | claimed |
| EP-1456203-B1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2008-08-20 | — | — | EP | claimed |
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2005-07-21 | — | — | US | claimed |
| US-7468367-B2 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-12-23 | — | — | US | disclosed |
| EP-1456203-B1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2005-07-21 | — | — | US | disclosed |
| EP-1456203-A1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003051872-A1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | HCRTR2, HCRTR1, GRPR | NPC1 1803/4885RAB9A 3522/4885SMN1; SMN2 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.